Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
1. An enema delivery system configured for transporting to a remote facility, the enema delivery system comprising a container, flexible tubing, and a pharmaceutical composition within the container, wherein the pharmaceutical composition is formulated for enema delivery from the container via the flexible tubing, wherein the pharmaceutical composition comprises saline, a cryoprotectant and a preparation of viable uncultured non-pathogenic fecal bacteria, wherein the fecal bacteria are from a stool of a human donor, wherein the container is sealed, wherein the pharmaceutical composition is free of rough particulate matter, and wherein the pharmaceutical composition is in an amount effective for treating recurrence of C. difficile infection.
2. The enema delivery system of claim 1 , wherein the cryoprotectant comprises polyethylene glycol.
3. The enema delivery system of claim 1 , wherein the saline comprises sodium chloride.
4. The enema delivery system of claim 1 , wherein the container comprises a polymer.
5. The enema delivery system of claim 4 , wherein the polymer comprises ethylene.
6. The enema delivery system of claim 1 , wherein the container comprises an oxygen-resistant material.
7. The enema delivery system of claim 1 , wherein the stool is derived from a healthy human donor.
8. The enema delivery system of claim 1 , wherein the preparation of viable uncultured non-pathogenic fecal bacteria comprises a non-selected population of fecal bacteria from the stool of the donor.
9. The enema delivery system of claim 1 , wherein the fecal bacteria are separated from fiber of the stool.
10. The enema delivery system of claim 1 , wherein the pharmaceutical composition is frozen.
11. The enema delivery system of claim 1 , wherein the pharmaceutical composition further comprises an antioxidant.
12. An enema product configured for transporting to a remote facility, the enema product comprising flexible tubing, a sealed bag, and a pharmaceutical composition within the bag, wherein the pharmaceutical composition is formulated for enema delivery from the bag, wherein the pharmaceutical composition comprises saline, a cryoprotectant and a suspension of viable non-pathogenic fecal bacteria, wherein the fecal bacteria are from a stool of a human donor, wherein the fecal bacteria are separated from rough particulate matter and are not cultured, and wherein the pharmaceutical composition is in an amount effective for treating recurrence of C. difficile infection.
13. The enema product of claim 12 , wherein the pharmaceutical composition is formulated for enema delivery directly from the bag via the flexible tubing.
14. The enema product of claim 12 , wherein the bag comprises a polymer comprising ethylene.
15. The enema product of claim 12 , wherein the bag comprises an oxygen-resistant material.
16. The enema product of claim 12 , wherein the cryoprotectant comprises polyethylene glycol.
17. The enema product of claim 12 , wherein the saline comprises sodium chloride.
18. The enema product of claim 12 , wherein the suspension of fecal bacteria comprises a non-selected population of fecal bacteria from the stool of the donor.
19. The enema product of claim 12 , wherein the pharmaceutical composition is frozen.
20. The enema product of claim 12 , wherein the fecal bacteria are separated from fiber of the stool.
21. The enema product of claim 12 , wherein the pharmaceutical composition further comprises an antioxidant.